In this study, we have established that resistance to BRAF inhibitors such as vemurafenib or dabrafenib alone or in combination with MEK1/2 inhibitor (trametinib) in melanoma cells was due to overexpression of Mcl-1. Here, MAP2K1 is linked to melanoma.